Ken J Snibson
Overview
Explore the profile of Ken J Snibson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
53
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Derseh H, Perera K, Dewage S, Stent A, Koumoundouros E, Organ L, et al.
Front Pharmacol
. 2021 Nov;
12:700902.
PMID: 34744706
Idiopathic pulmonary fibrosis (IPF) is a progressive chronic lung disease characterized by excessive extracellular matrix (ECM) deposition in the parenchyma of the lung. Accompanying the fibrotic remodeling, dysregulated angiogenesis has...
2.
Derseh H, Dewage S, Perera U, Koumoundouros E, Pagel C, Organ L, et al.
Exp Lung Res
. 2021 Aug;
46(10):409-419.
PMID: 34346276
Background: Although IPF is described traditionally as a disease affecting lung parenchyma, there is renewed interest in the alterations in the structure and function of the small airways in both...
3.
Derseh H, Dewage S, Perera K, Pagel C, Koumoundouros E, Organ L, et al.
Sci Rep
. 2019 Dec;
9(1):19893.
PMID: 31882807
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with limited therapeutic options and poor prognosis. IPF has been associated with aberrant vascular remodelling, however the role of vascular...
4.
Dewage S, Organ L, Koumoundouros E, Derseh H, Perera K, Samuel C, et al.
Exp Lung Res
. 2019 Nov;
45(9-10):310-322.
PMID: 31762329
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive fibrotic lung disease with unknown cause. While the drugs nintedanib and pirfenidone have been approved for the treatment of IPF, they only...
5.
Organ L, Bacci B, Koumoundouros E, Kimpton W, Samuel C, Nowell C, et al.
Am J Respir Cell Mol Biol
. 2017 Jan;
56(4):539-550.
PMID: 28060543
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive disease of increasing prevalence marked by poor prognosis and limited treatment options. Ca-activated K3.1 potassium channels have been shown to play a...
6.
El Mays T, Choudhury P, Leigh R, Koumoundouros E, Van Der Velden J, Shrestha G, et al.
Respir Res
. 2014 Oct;
15:98.
PMID: 25355286
Background: The low toxicity of perfluorocarbons (PFCs), their high affinity for respiratory gases and their compatibility with lung surfactant have made them useful candidates for treating respiratory diseases such as...
7.
Bischof R, Snibson K, Van Der Velden J, Meeusen E
J Inflamm (Lond)
. 2008 Oct;
5:16.
PMID: 18937841
Background: House dust mite (HDM) allergens are a major cause of allergic asthma. Most studies using animal models of allergic asthma have used rodents sensitized with the 'un-natural' allergen ovalbumin....